Spinal Muscular Atrophy (SMA) Treatment Market Report 2020, & Forecast 2021-2026(Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Spinal Muscular Atrophy (SMA) Treatment Market


The global Spinal Muscular Atrophy (SMA) Treatment market size is projected to reach US$ 2633.6 million by 2026, from US$ 1271.71 million in 2020, at a CAGR of 12.9% during 2021-2026. Increasing awareness regarding Spinal Muscular Atrophy (SMA) and growing number of initiatives to improve treatment options for rare diseases are among key factors augmenting the market development. For example, the enactment of Orphan Drug Act, 1983 in U.S. and a similar act for orphan medicinal products in EU has increased the importance of research activities for the management of rare diseases.

In 2017, U.S. FDA granted an orphan drug license to RG7916, a joint development program by Roche, SMA Foundation, and PTC Therapeutics for the treatment of SMA. Similarly, the Orphan Drug Designation was also granted to Cytokinetics CK-2127107 by U.S. FDA in May 2017. This is expected to accelerate the number of clinical researches in this field, thereby propelling the market growth.

Moreover, initiatives undertaken by various public, as well as nonprofit, organizations for creating awareness regarding SMA is another factor driving the market. In January 2018, National Institute for Health and Care Excellence (NICE) invited Biogen to submit a single technology appraisal for Spinraza to enable NHS funding. NICE and NHS, U.K. are developing a managed access agreement for a long-term reimbursement plan for Biogens Spinraza.

In addition, organizations, such as Cure SMA, SMA Foundation, and Muscular Dystrophy Association, are creating awareness about this disorder. Major companies are heavily investing in R & D for the development of a curative treatment. All these factors are also contributing towards market growth. Research institutes are also focusing on the development of treatment therapy for this disorder.

Some of the products in the clinical pipeline are AVXS-101, a gene therapy under clinical research developed by AveXis, Inc. and Roche Holding AGs Olesoxime, an investigational therapy being developed for promoting the survivor of motor neurons. Several other products in the clinical pipeline are Ck-2127107 (Cytokinetics), Branaplam (Novartis), VY-SMN101 (Voyager Therapeutics), and Bbrm02 (BioBlast Pharma).

Market Segmentation, Outlook & Viewpoint: Global Spinal Muscular Atrophy (SMA) Treatment Market

Disease Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Type 1
  
Type 2
  
Type 3
  
Type 4

Treatment Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Gene Therapy
  
Drug
  
Spinraza
  
RG6083 (Olesoxime)
  
RG7916

Route of Administration Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Oral
  
Intrathecal

Key Players, Recent Developments & Regional Insights: Global Spinal Muscular Atrophy (SMA) Treatment Market

In 2017, type 1 SMA emerged as the largest segment of the spinal muscular atrophy treatment market. This segment is expected to register the fastest CAGR over the forecast period as it is one of the most common forms. Increasing incidences of this type and focus of companies on developing drugs for SMA treatment are the key factors contributing to the segments largest revenue share. AVXS-101 is an investigational gene therapy developed by AveXis, Inc. This therapy is being tested in a clinical trial STR1VE for evaluating the safety and efficacy of one-time infusion of AVXS-101 in SMA 1 patients.

Another example of investigational therapy focused on Type 1 SMA is Novartis AGs LMI070. Thus, increasing number of clinical studies focused on type 1 disease is the major factor boosting the segment growth. Spinraza is the available treatment for all types of SMA. AveXis, Inc. has undertaken a clinical trial STRONG to evaluate the safety, efficacy, and optimal dosing of AVXS-101 in type 2 SMA patients among two distinct age groups. Thus, clinical researches for extending indications to other SMA types is anticipated to boost the market.

Regional Insights

North America led the market in 2017. This growth was due to maximum revenue generated by U.S. market. Since Spinraza was approved in the country in December 2016. Some of the other factors that contributed to the largest revenue share is the presence of Biogen Inc. in U.S., high disposable income, and rise in the adoption of Spinraza. The market will expand further on account of a number of initiatives undertaken by private organizations to create awareness and support R & D for the treatment of this disorder.

For example, CureSMA is an organization dedicated to funding and supporting comprehensive research to boost the treatment and care for SMA patients and their families. Asia Pacific is expected to register the fastest CAGR over the forecast period. This growth is attributed to the rapidly developing health infrastructure in countries, such as China and India, and increasing number of initiatives to improve the access tSMA therapies. Rise in consumer disposable income is also expected to positively influence the market growth.

Spinal Muscular Atrophy Treatment Market Share Insights

The market is led by Biogen, Inc. Biogens Spinraza is the only approved commercialized treatment for this disorder. Thus, competitive rivalry for this market is extremely low. However, this trend will change with the commercialization of several products. For instance, the products of Roche and Avexis, Inc. are under phase 3 clinical study. These products are likely to be commercialized in the coming years and this is anticipated to increase competition.

Key Insights Covered: Global Spinal Muscular Atrophy (SMA) Treatment Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Spinal Muscular Atrophy (SMA) Treatment industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Spinal Muscular Atrophy (SMA) Treatment industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Spinal Muscular Atrophy (SMA) Treatment industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Spinal Muscular Atrophy (SMA) Treatment industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Spinal Muscular Atrophy (SMA) Treatment industry.

Research Methodology: Global Spinal Muscular Atrophy (SMA) Treatment Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other